Moderna's new version of its COVID-19 vaccine, which targets two virus variants ... states " will have the possibility to receive the expected updated bivalent booster candidate following approval ...

Shares of Moderna tumbled in early trading Monday after the vaccine maker predicted a steeper-than-expected sales drop in the new year. Moderna said it expects 2025 revenue to range between $1.5 ...

There are currently three vaccine candidates moving through the clinical pipeline in human trials right now, and the furthest along is Moderna ... of which are expected to be circulating Something ...

As Moderna maps out a more cautious future amid lower-than-expected sales of its current products, the company is bolstering ...

Shares of Moderna tumbled Monday after the vaccine maker predicted a steeper-than-expected sales drop in the new year ...

Norovirus, often erroneously called the "stomach flu," sickens an estimated 21 million Americans and 685 million people worldwide every year, and though there is currently no preventive vaccine ...